The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive Purchase Agreement pursuant to which BioNTech intends to ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Drugmaker GSK said on Friday that it had reached a settlement, alongside CureVac, to resolve long-running patent litigation ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

CureVac ended the first quarter of 2025 with a cash reserve of €438 million, which is expected to sustain the company’s operations into 2028, supporting its impressive 87.62% gross profit margin. The ...

Investing.com -- GSK (NYSE: GSK) (LON: GSK) said on Monday that the U.S. Food and Drug Administration has accepted its ...

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...